Literature DB >> 24711569

Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells.

Lars Tramsen1, Stanislaw Schmidt, Frauke Roeger, Ralf Schubert, Emilia Salzmann-Manrique, Jean-Paul Latgé, Thomas Klingebiel, Thomas Lehrnbecher.   

Abstract

Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive aspergillosis. Whereas adoptive immunotherapy transferring donor-derived anti-Aspergillus TH1 cells has been shown to be beneficial for HSCT recipients suffering from invasive aspergillosis, little is known about the impact of commonly used immunosuppressants on the functional properties of anti-Aspergillus TH1 cells. Anti-Aspergillus TH1 cells were coincubated with different concentrations of methylprednisolone, cyclosporine (CsA), mycophenolic acid (MPA), the active component of mycophenolate mofetil, and rapamycin. Immunosuppressants were tested in concentrations reflecting common target levels in serum and in significantly lower and higher concentrations. Apoptosis of anti-Aspergillus TH1 cells, as well as proliferation and production of gamma interferon (IFN-γ) and CD154 upon restimulation, was evaluated in the presence and absence of immunosuppressive compounds. All dosages of CsA, MPA, and methylprednisolone significantly decreased the number of viable anti-Aspergillus TH1 cells in the cell culture, which was due partly to an impaired proliferative capacity of the cells and partly to an increased rate of apoptosis. In addition, CsA significantly decreased the number of IFN-γ-producing cells and had the highest impact of all immunosuppressants on IFN-γ levels in the supernatant. CsA also significantly decreased the expression of CD154 by anti-Aspergillus TH1 cells. Variant dosages of immunosuppressants exhibit particular effects on essential functional properties of anti-Aspergillus TH1 cells. Our findings may have an important impact on the design of clinical trials evaluating the therapeutic benefit of anti-Aspergillus TH1 cells in allogeneic HSCT recipients suffering from invasive aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24711569      PMCID: PMC4019178          DOI: 10.1128/IAI.01700-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.

Authors:  T Ruutu; A van Biezen; B Hertenstein; A Henseler; L Garderet; J Passweg; M Mohty; A Sureda; D Niederwieser; A Gratwohl; T de Witte
Journal:  Bone Marrow Transplant       Date:  2012-03-12       Impact factor: 5.483

Review 2.  Calcineurin inhibitors and NFAT-regulated gene expression.

Authors:  Claudia Sommerer; Stefan Meuer; Martin Zeier; Thomas Giese
Journal:  Clin Chim Acta       Date:  2011-10-05       Impact factor: 3.786

3.  Cyclosporin A and tacrolimus reduce T-cell polyfunctionality but not interferon-γ responses directed at cytomegalovirus.

Authors:  Stephan Fuhrmann; Raskit Lachmann; Mathias Streitz; Roland Hetzer; Hans-Dieter Volk; Hans Lehmkuhl; Florian Kern
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

Review 4.  The influence of mTOR on T helper cell differentiation and dendritic cell function.

Authors:  Robert J Salmond; Rose Zamoyska
Journal:  Eur J Immunol       Date:  2011-07-04       Impact factor: 5.532

5.  Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation.

Authors:  X He; R L Smeets; H J P M Koenen; P M Vink; J Wagenaars; A M H Boots; I Joosten
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

6.  Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling.

Authors:  Adrian Egli; Deepali Kumar; Chris Broscheit; Daire O'Shea; Atul Humar
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

Review 7.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

Review 8.  New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation.

Authors:  Sofie Vandevyver; Lien Dejager; Jan Tuckermann; Claude Libert
Journal:  Endocrinology       Date:  2013-02-05       Impact factor: 4.736

9.  Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.

Authors:  Rakesh K Goyal; Kelong Han; Donna A Wall; Michael A Pulsipher; Nancy Bunin; Stephan A Grupp; Sripal R Mada; Raman Venkataramanan
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-21       Impact factor: 5.742

10.  Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells.

Authors:  Kenshiro Tsuda; Keiichi Yamanaka; Hiroshi Kitagawa; Tomoko Akeda; Masanao Naka; Kaori Niwa; Takehisa Nakanishi; Masato Kakeda; Esteban C Gabazza; Hitoshi Mizutani
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  7 in total

1.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

2.  Glucocorticoids Suppress Antimicrobial Autophagy and Nitric Oxide Production and Facilitate Mycobacterial Survival in Macrophages.

Authors:  Jinli Wang; Ruining Wang; Hui Wang; Xiaofan Yang; Jiahui Yang; Wenjing Xiong; Qian Wen; Li Ma
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

Review 3.  Immunomodulation as Therapy for Fungal Infection: Are We Closer?

Authors:  Qi Hui Sam; Wen Shan Yew; Chaminda J Seneviratne; Matthew Wook Chang; Louis Yi Ann Chai
Journal:  Front Microbiol       Date:  2018-07-25       Impact factor: 5.640

4.  Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.

Authors:  Sebastian Wurster; Nathaniel D Albert; Uddalak Bharadwaj; Moses M Kasembeli; Jeffrey J Tarrand; Naval Daver; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

Review 5.  Adoptive T-cell therapy for fungal infections in haematology patients.

Authors:  Shivashni S Deo; David J Gottlieb
Journal:  Clin Transl Immunology       Date:  2015-08-14

6.  Distinct Effects of Immunosuppressive Drugs on the Anti-Aspergillus Activity of Human Natural Killer Cells.

Authors:  Stanislaw Schmidt; Ralf Schubert; Asuman Demir; Thomas Lehrnbecher
Journal:  Pathogens       Date:  2019-11-19

Review 7.  Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.

Authors:  Muluneh Ademe
Journal:  Front Cell Infect Microbiol       Date:  2020-09-15       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.